sorafenibRegorafenibHCChepatocellular carcinoma
…in this study (from January 2022 to January 2025), who received sorafenib treatment according to the BCLC staging system.Fifty-five patie…
13articles mentioning drugs
31drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: sorafenib ×
sorafenib
This drug is selected. Its supporting articles are shown below.
Articles mentioning sorafenib
13 articles · page 1 of 2LenvatinibSorafenibAtezolizumabBevacizumab
…. For HCC-specific mortality, higher risks were associated with Lenvatinib (aHR 9.04; 95%CI 3.36-24.3; p<0.001), Sorafenib (aHR 5.82; 95%C…
sorafenibHCChepatocellular carcinomaliver cancer
…the CD133+ stem/progenitor population, and sensitizes tumors to sorafenib.Conclusions MYEF2 is a liver cancer stem/progenitor–specific re…
pemigatinibsorafenibglaucomaFood and Drug Administration-approvedsurgical intervention
…, was the main driver of wound closure. Among the drugs tested, pemigatinib and sorafenib significantly slowed wound closure. Pemigatinib s…
pembrolizumabbortezomibcrizotinibpembrolizumab35sunitinibdasatinib
…umab) are often used in ovarian and cervical cancers. ICIs (eg, pembrolizumab) are effective in mismatch repair-deficient endometrial cancer …
99.8%
sorafenibHCChepatocellular carcinoma
… evaluate the effect of CD24 on the sensitivity of HCC cells to sorafenib. The integration of RNA sequencing, flow cytometry, cell chemot…
sorafeniblenvatinibnivolumabipilimumabNIVOSORIPILEN
… trial assessing nivolumab plus ipilimumab versus lenvatinib or sorafenib for unresectable hepatocellular carcinoma in the first-line set…
lenvatinibsorafenibAtezolizumab-Bevacizumabhepatocellular carcinomatertiary hospital
…41% ECOG 1 (n=18). Previous treatments were sorafenib (n=3) and lenvatinib (n=2).The median number of cycles received was 10 (4-54). The r…
sorafeniblenvatinibMASLD-HCCMetabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma (MASLD-HCC)first-line therapy
…y of CD133-siRNA nanoparticles potently sensitised MASLD-HCC to sorafenib and lenvatinib, significantly improving outcomes in MASLD-HCC.C…
sorafeniblenvatinibnivolumabatezolizumabHepatocellular carcinomaHCCtyrosine kinase inhibitors
…e very limited. For decades, tyrosine kinase inhibitors such as sorafenib and lenvatinib have been the only first-line treatments for adv…
lenvatinibsorafenibatezolizumab-bevacizumabpembrolizumabProton-TKIProton radiotherapyLinkou Chang Gung Memorial Hospitalhepatocellular carcinomaHCCProton-TKI
…mbrolizumab (n = 5). Tyrosine kinase inhibitors (TKIs) included lenvatinib (n = 16) and sorafenib (n = 13).Results With a median follow-up…
sorafenibnivolumabBayerHCCUCSF Institutional Review BoardNational Institutes of HealthBMSimCORE NetworkCPABili Project Foundation, Inc.+1 more
…to assess the safety and efficacy of the multikinase inhibitor, sorafenib, combined with ICI nivolumab (anti-PD-1), in 16 patients with H…